Literature DB >> 3579609

Protective effect of antibodies to two viral envelope glycoproteins on lethal infection with Newcastle disease virus.

Y Umino, T Kohama, M Kohase, A Sugiura, H D Klenk, R Rott.   

Abstract

The protective effect of humoral immunity against lethal infection of chickens with Newcastle disease virus was studied. Chickens hatched from eggs laid by hens vaccinated with live attenuated Newcastle disease virus vaccine possessed antibody to various components of the virus, and were resistant to a challenge with a virulent strain of Newcastle disease virus which was 100 per cent fatal for the offspring of nonvaccinated hens. Passive administration of antiserum raised against whole virions provided susceptible chickens protection comparable to that seen in the birds with maternal antibody. When administered passively, both anti-HN serum with virus neutralizing activity, and anti-F serum with only marginal virus neutralizing activity significantly prolonged the survival of infected birds but failed to achieve the level of protection as afforded by the anti-whole NDV serum. The protection provided by the simultaneous presence of anti-HN and anti-F serum was significantly greater than that afforded by either alone and comparable to that of anti-whole NDV serum, indicating the complementary effect of anti-HN and anti-F antibodies not only in cell cultures as reported previously (19), but also in a natural host.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579609     DOI: 10.1007/bf01313728

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  17 in total

1.  The influence of passive immunity or the response to intramuscular and intranasal administration of Newcastle disease virus.

Authors:  F R BEAUDETTE; J A BIVINS
Journal:  Cornell Vet       Date:  1953-10

2.  Transmission of antiviral activity via the egg and the rôle of congenital passive immunity to Newcastle disease in chickens.

Authors:  C A BRANDLY; H E MOSES
Journal:  Am J Vet Res       Date:  1946-07       Impact factor: 1.156

3.  Evaluation of survival in challenge experiments.

Authors:  F D Liddell
Journal:  Microbiol Rev       Date:  1978-03

4.  Antigenic mapping and functional analysis of the F protein of Newcastle disease virus using monoclonal antibodies.

Authors:  G Abenes; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

5.  Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis.

Authors:  A Löve; R Rydbeck; G Utter; C Orvell; K Kristensson; E Norrby
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

Review 6.  Virulence in Newcastle disease virus. A preliminary study.

Authors:  A P Waterson; T H Pennington; W H Allan
Journal:  Br Med Bull       Date:  1967-05       Impact factor: 4.291

7.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

8.  Biological functions of monospecific antibodies to envelope glycoproteins of Newcastle disease virus.

Authors:  Y Umino; T Kohama; M Kohase; A Sugiura; H D Klenk; R Rott
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

9.  Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity.

Authors:  P Giraudon; T F Wild
Journal:  Virology       Date:  1985-07-15       Impact factor: 3.616

Review 10.  Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.

Authors:  D C Merz; A Scheid; P W Choppin
Journal:  J Exp Med       Date:  1980-02-01       Impact factor: 14.307

View more
  7 in total

1.  Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.

Authors:  K Sonoda; M Sakaguchi; H Okamura; K Yokogawa; E Tokunaga; S Tokiyoshi; Y Kawaguchi; K Hirai
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens.

Authors:  Sachin Kumar; Baibaswata Nayak; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

3.  Construction of a camelid VHH yeast two-hybrid library and the selection of VHH against haemagglutinin-neuraminidase protein of the Newcastle disease virus.

Authors:  Xiaolong Gao; Xiangyun Hu; Lina Tong; Dandan Liu; Xudong Chang; Haixin Wang; Ruyi Dang; Xinglong Wang; Sa Xiao; Enqi Du; Zengqi Yang
Journal:  BMC Vet Res       Date:  2016-02-26       Impact factor: 2.741

4.  Development of a novel Newcastle disease virus (NDV) neutralization test based on recombinant NDV expressing enhanced green fluorescent protein.

Authors:  Ana Chumbe; Ray Izquierdo-Lara; Katherine Calderón; Manolo Fernández-Díaz; Vikram N Vakharia
Journal:  Virol J       Date:  2017-11-23       Impact factor: 4.099

5.  Identification of a potential neutralizing linear epitope of hemagglutinin-neuraminidase in Newcastle disease virus.

Authors:  Zhongyuan Jin; Qiaolin Wei; Youkun Bi; Yongshan Li; Na Huo; Sujing Mou; Wenbin Wang; Haijin Liu; Zengqi Yang; Hongjun Chen; Sa Xiao
Journal:  Virol J       Date:  2021-01-06       Impact factor: 4.099

Review 6.  Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems.

Authors:  Chris J Hedegaard; Peter M H Heegaard
Journal:  Vet Immunol Immunopathol       Date:  2016-04-26       Impact factor: 2.046

7.  Characterization of haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed by a recombinant baculovirus.

Authors:  M Niikura; Y Matsuura; M Hattori; M Onuma; T Mikami
Journal:  Virus Res       Date:  1991-06       Impact factor: 3.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.